Skip to Main Content
Contribute Try STAT+ Today

For a more detailed rundown of Friday’s meeting, with slides from the presentations, click here.

A panel of outside experts resoundingly concluded Friday that clinical data did not support the approval of Biogen’s much-watched Alzheimer’s drug, aducanumab, while providing a rebuke to the Food and Drug Administration, whose reviewers had given the medicine a glowing appraisal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Speaking as a layman, not a medical person, I am infuriated that the FDA might approve yet another useless drug to fight Alzheimers. Aricept, Namenda, and the Excelon Patch do no good yet once started, you are afraid to stop because there is nothing else. Meanwhile the march to loss of dignity continues to the point you wish for death. I have no respect for the FDA.

  • The FDA seems to have given up on pretending they work for the people. It’s all about servicing the careers of FDA employees, who hope to get a job in industry after their stint at the agency. They are all just a bunch of sycophants to industry executives. We saw Sarepta, now this, and everything in between.

  • Billy Dunn, should resign or be replaced- NOW! Full stop.

    The first question that his group crafted for the Advisory Panel had the gall to ask the Advisory Committee to literally endorse “cherry picking” clinical trials.

    “Does Study 302, viewed independently and without regard for Study 301, provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease? ”

    No one who thinks that it is okay to flatly ignore clinical trials that don’t give the desired read out has any business working at the FDA.

    To Stephen Hahn- do the right thing!

  • it seems like that after all that happened in this Trump infused FDA, they just stopped pretending they are a serious overseeing agency with scientific integrity altogether

Comments are closed.